جست‌وجوی استاد و پژوهشگر

Roel Verhaakمشاهده پروفایل

استاد

• Brain Tumor Research
• Glioma Evolution
• Extrachromosomal DNA Amplification
• +۵ مورد دیگر

Roel Verhaak, PhD, is a Professor in the Department of Neurosurgery at the Yale School of Medicine, holding the prestigious Harvey and Kate Cushing Professorship. He maintains extensive affiliations across Yale's research ecosystem, including the Genomics, Genetics, and Epigenetics Program, Human Genome Sciences, Molecular Medicine, Pharmacology, and Physiology, the Neurosurgery Program in Translational Biomedicine, and the Yale Cancer Center. Dr. Verhaak earned his PhD from Erasmus University Medical Center in Rotterdam, followed by postdoctoral training at the Broad Institute/Dana-Farber Cancer Institute. He established his independent research program at MD Anderson Cancer Center in 2010, was affiliated with the Jackson Laboratory for Genomic Medicine from 2016, and joined Yale School of Medicine in 2023. His research focuses on brain tumors and extrachromosomal DNA amplification in cancer. The Verhaak Lab studies tumor evolution and therapy resistance mechanisms in gliomas using high-throughput sequencing, computational analysis, and functional studies. He leads the Glioma Longitudinal Analysis Consortium (GLASS) and made the groundbreaking discovery that extrachromosomal DNA amplifications are critical cancer drivers. Dr. Verhaak's publication record shows a consistent focus on advancing our understanding of glioma biology and cancer genomics, with recent work (2023-2025) emphasizing extrachromosomal DNA mechanisms, glioma evolution, and novel therapeutic approaches. His research has shifted from initial molecular classification work to deeper mechanistic understanding of tumor evolution and resistance. AAAS Martin and Rose Wachtel Cancer Research Award (2016) Adult Basic Science Award from the Society for Neuro-Oncology (2014) Peter Steck Memorial Award from the Pediatric Brain Tumor Foundation (2012) Wilson S. Stone Memorial Award from MD Anderson Cancer Center (2011) Dr. Verhaak actively mentors researchers and collaborates extensively across institutions. He co-founded Boundless Bio to translate his discoveries about extrachromosomal DNA into therapeutic approaches. His lab participates in major consortia including the GBM Cellular Analysis of Resistance and Evolution (CARE) consortium, which has refined our understanding of glioblastoma's cellular architecture through single-cell transcriptomics. The Verhaak Lab maintains a strong research presence with multiple active projects focused on understanding how extrachromosomal DNA drives cancer progression and developing strategies to target this mechanism therapeutically.

Shiqiang Taoمشاهده پروفایل

دانشیار

• Neuro-informatics
• Clinical Data Management
• Deep Learning
• +۱ مورد دیگر

Dr. Shiqiang Tao is an Associate Professor at McGovern Medical School, The University of Texas Health Science Center at Houston. His academic journey includes prior roles as an Assistant Professor at the University of Kentucky's Department of Internal Medicine, Lead Developer at Kentucky's Institute of Biomedical Informatics, and Research Associate at Case Western Reserve University's Center for Clinical Investigation. His research centers on neuro-informatics with two primary thrusts: Ontology-driven Clinical Data Management : Involving data integration, cross-cohort querying, visualization, and temporal analysis for healthcare datasets. Deep Learning in Healthcare : Applied to substance use disorder prediction, sleep spindle detection/sub-typing, and postictal generalized EEG suppression (PGES) identification. Dr. Tao's publications (2014–2018) demonstrate consistent focus on medical informatics innovations, including sleep data repositories, clinical trial automation, SNOMED CT mining, and neurotechnology interfaces. His work emphasizes scalable data solutions and ontology-based frameworks.

Benedetto Farinaمشاهده پروفایل

استاد

• Clinical Psychology
• Neurophysiology of Psychopathology
• Trauma and Dissociation
• +۴ مورد دیگر

Benedetto Farina is a Full Professor of Clinical Psychology at Università Europea di Roma with extensive international engagements. His academic roles include: Teaching at Universitat de Barcelona's Master Course on Cognitive Social Therapy Scientific Advisory Board membership for the International Society for the Study of Trauma and Dissociation Editorial positions at four peer-reviewed journals including Journal of Trauma and Dissociation and Clinical Neuropsychiatry His research focuses on three interconnected domains: Neurophysiology of Psychopathology : Investigating EEG correlates of trauma, dissociation, and eating disorders through advanced connectivity analyses Attachment and Trauma : Examining disintegrative pathogenic processes in developmental trauma using neurobiological frameworks Psychotherapy Mechanisms : Studying relational foundations of therapeutic interventions and metacognitive development Farina's 100+ publications demonstrate consistent focus on neuro-clinical interfaces. Recent work (2018-2020) emphasizes quantitative EEG studies of religious coping, cannabis use neurophysiology, default mode network alterations in anxiety/depression, and attachment memory impacts. Methodologically, 80% of recent articles utilize EEG/neuroimaging techniques applied to clinical populations. He maintains active teaching responsibilities across 20+ psychotherapy specialization programs internationally. His seminars on trauma and dissociation have been delivered to academic institutions and healthcare organizations worldwide for over 15 years.

Joelle Payne Straehlaمشاهده پروفایل

استادیار

• Cancer nanomedicine
• Drug delivery technologies
• Pediatric brain tumors
• +۵ مورد دیگر

Dr. Joelle Payne Straehla is an Assistant Professor of Pediatrics at the University of Washington School of Medicine and an Adjunct Assistant Professor of Bioengineering. She serves as a principal investigator at Seattle Children's Research Institute and as a pediatric oncologist in the Brain Tumor Program at Seattle Children's Hospital. Dr. Straehla is also a member of the Fred Hutch/University of Washington/Seattle Children's Cancer Consortium. Dr. Straehla received her MD from Northwestern University Feinberg School of Medicine and completed her pediatric residency at Seattle Children's Hospital/University of Washington. She further completed a fellowship in pediatric hematology/oncology at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, where she gained additional training in biological and chemical engineering in the laboratory of Dr. Paula Hammond at Massachusetts Institute of Technology. Prior to joining Seattle Children's in 2024, she was an Instructor of Pediatrics at Harvard Medical School and a Charles W. (1955) and Jennifer C. Johnson Clinical Investigator at MIT's Koch Institute for Integrative Cancer Research. Dr. Straehla's research focuses on advancing drug delivery technologies for pediatric cancers, with a special interest in cancer nanomedicine. Her work operates at the intersection of nanotechnology and cancer biology, aiming to bridge the gap between innovative engineering tools and clinical practice. She leads the Straehla Lab, which is dedicated to designing new nanoparticle-based therapeutics, identifying biological regulators of nanoparticle drug delivery, improving delivery across challenging tissue barriers, and developing strategies to remodel the tumor microenvironment. Her research has significant implications for improving treatment of pediatric brain tumors and other difficult-to-treat childhood cancers. Dr. Straehla's publication record demonstrates expertise in nanoparticle design, blood-brain barrier penetration, and targeted cancer therapies. Her work includes developing predictive microfluidic models of glioblastoma, identifying biomarkers for nanoparticle delivery (particularly SLC46A3), and engineering layer-by-layer nanoparticles for improved brain tumor targeting. Her research combines high-throughput screening, genomic analysis, and translational approaches to accelerate the development of nanomedicine for pediatric cancer patients. Among her notable recognitions is the Charles W. (1955) and Jennifer C. Johnson Clinical Investigator position at MIT's Koch Institute for Integrative Cancer Research. Her work has been published in high-impact journals including Science, Proceedings of the National Academy of Sciences, and ACS Nano. As a clinician, Dr. Straehla cares for children with brain and spinal cord tumors and is involved in local and national consortia focused on improving brain tumor drug delivery through collaborative research. She is committed to harnessing cutting-edge engineering methods to improve outcomes for children with cancer while minimizing side effects to the developing brain. The Straehla Lab operates at the Ben Towne Center for Childhood Cancer and Blood Disorders Research and includes a diverse team of researchers working on various aspects of nanomedicine and drug delivery. Current projects include unlocking the drivers of nanoparticle delivery, engineering combination nanomedicines, and developing precision drug carriers for the central nervous system.

• Cancer Biology
• Tumor Heterogeneity
• Glioblastoma
• +۴ مورد دیگر

Michalina Janiszewska serves as an Assistant Professor at the University of Florida, leading the SR-MM-JANISZEWSKA LAB focused on unraveling intratumor heterogeneity in aggressive brain tumors. Her research bridges molecular oncology and clinical translation to address therapy resistance mechanisms. Her academic foundation includes a Ph.D. in Life Sciences from the University of Lausanne (2012), a Master's in Medical Biotechnology from the University of Wroclaw (2007), and a Bachelor's in Biotechnology from the same institution (2005). Prior to her current role, she completed postdoctoral fellowships at Dana-Farber/Harvard Cancer Center (2012-2016) and CHUV-Lausanne University Hospital. Dr. Janiszewska's research spans Cancer Biology, Tumor Heterogeneity, Glioblastoma, Breast Cancer, and Precision Medicine. Her lab investigates how subclonal cancer cell populations interact with the tumor microenvironment to drive disease progression, with emphasis on spatial transcriptomics, epigenetic regulation, and immune modulation. She employs single-cell and spatial analysis techniques to dissect tumor complexity. Analysis of her 15 most recent publications reveals dominant themes in glioblastoma heterogeneity (2023-2025), EGFR/CDK4 co-amplification dynamics (2023), and PIK3CA-related therapeutic vulnerabilities (2024). Her work consistently links molecular alterations to clinical resistance patterns across brain and breast cancers. She currently manages three active grants: Principal Investigator for 'Oncofetal protein as a therapeutic target in pediatric brain tumors' (FL DEPT OF HLTH LIVE LIKE BELLA, 2024), 'Scott R. MacKenzie Foundation Final Grant' (UF FOUNDATION, 2023), and Project Manager for the American Cancer Society Institutional Research Grant (2022). The SR-MM-JANISZEWSKA LAB operates from the University of Florida Scripps Biomedical Research campus in Jupiter, FL, with a mission to decode tumor ecosystem interactions for developing novel brain tumor therapies. The lab emphasizes translational approaches to convert heterogeneity insights into clinical strategies.

Yao Wanمشاهده پروفایل

دانشیار

• Artificial Intelligence
• Software Engineering
• Natural Language Processing
• +۳ مورد دیگر

Yao Wan is an Associate Professor at the School of Computer Science and Technology, Huazhong University of Science and Technology (HUST) in Wuhan, China. He leads the ONE Lab, focused on empowering machines to interact with the physical world through unified natural language interfaces (Language + X paradigm). He obtained his Ph.D. from Zhejiang University and has research visiting experience at Chinese University of Hong Kong, University of Technology Sydney, and University of Illinois Chicago. His research bridges Artificial Intelligence and Software Engineering, with core interests in: Natural Language Processing for code intelligence Large Language Model applications Multimodal learning across code, vision, and UI domains Program analysis and code generation Software engineering automation His publications demonstrate strong focus on applying transformer-based models to software engineering challenges, with recent work expanding into multimodal applications. Research spans code model security, GUI generation, data visualization, and compiler understanding, predominantly using deep learning approaches. Awards: IEEE TCSE Distinguished Paper Award for SANER 2025 publication He actively mentors students through the ONE Lab and serves on program committees for top conferences including ASE, ISSTA, and ICSE. He is seeking highly-motivated undergraduate researchers to join his team. The ONE Lab conducts cutting-edge research at the intersection of programming languages and artificial intelligence, with ongoing projects in code intelligence, multimodal learning, and LLM applications for software engineering.

James Hicksمشاهده پروفایل

استاد

• Single Cell Genomics
• Cancer Research
• Liquid Biopsy
• +۵ مورد دیگر

Dr. James Hicks serves as Professor of Research in the Department of Biological Sciences at the University of Southern California's Dornsife College of Letters, Arts and Sciences, and as Deputy Director of the Convergent Science Institute in Cancer (CSI-Cancer) at the USC Michelson Center. A pioneer in single cell genomics and translational cancer research, Dr. Hicks focuses on breast and prostate cancer through the development of high-content single cell assays to understand cancer's spatial and temporal evolution in the human body. Trained initially at the University of Oregon, Dr. Hicks built his career through research and faculty appointments at Cornell University and Cold Spring Harbor Laboratory before joining USC in 2014. His groundbreaking work at Cold Spring Harbor Laboratory enabled routine whole genome analysis of individual cells applied to solid tumor biopsies, establishing him as a leader in the field. At CSI-Cancer, his research expands to systemic diseases including cardiovascular disease, rheumatoid arthritis, and diabetes, addressing challenges of disease evolution under natural and therapeutic pressures. Dr. Hicks' research program represents a unique bridge between academic excellence and corporate entrepreneurship, with a proven track record of translating scientific discoveries into practical applications. His work on liquid biopsy technologies has positioned him at the forefront of cancer diagnostics, with over one hundred scientific papers and patents to his name, alongside multiple founded companies. The Convergent Science Institute under his deputy directorship integrates patient data, model systems, and high-content single cell analysis with advanced machine learning to translate clinical observations into mechanistic understanding of cancer dynamics across cellular, human, and population scales. Analysis of his recent publication record (2024-2025) reveals consistent innovation across multiple cancer types including breast, prostate, lung, pancreatic, and retinoblastoma. His research demonstrates sophisticated integration of single-cell analysis with liquid biopsy approaches, establishing new standards for cancer detection, monitoring treatment response, and understanding tumor heterogeneity. Notably, his work spans from fundamental genomic discoveries to clinical applications, with particular emphasis on developing more sensitive diagnostic methods and understanding the evolutionary dynamics that drive treatment resistance. As Deputy Director of CSI-Cancer, Dr. Hicks plays a critical role in advancing the institute's mission to enhance cancer patient care through convergent science that brings together researchers across disciplines. His leadership extends to the DoD-funded Convergent Science Cancer Consortium, which includes collaborations with Cedars-Sinai, Children's Hospital Los Angeles, and Stanford University, demonstrating his significant impact on the broader cancer research community.

• Spiking Neural Networks
• Neuromorphic Information Processing
• Artificial Neural Networks
• +۷ مورد دیگر

Professor Martin Bogdan serves as a Professor for Neuromorphic Information Processing at the University of Leipzig within the Faculty of Mathematics and Computer Science. His research spans multiple interdisciplinary domains including spiking neural networks, neuromorphic computing, and medical signal processing applications. University: University of Leipzig School: Faculty of Mathematics and Computer Science Department: Department of Neuromorphic Information Processing Office: Augustusplatz 10, Room P 531, 04109 Leipzig Contact: +49 (341) 97-32208 | bogdan@informatik.uni-leipzig.de Professor Bogdan completed his doctorate at the University of Tübingen in 1998 with research focused on signal processing of biological nerve signals for controlling prostheses using artificial neural networks. His educational background includes communications engineering at Offenburg University of Applied Sciences and studies at Université Grenoble I Joseph Fourier. Professor Bogdan's research interests center on neuromorphic information processing, with particular emphasis on spiking neural networks (SNNs), neurological plausible learning algorithms, and the incorporation of dynamics within synaptic efficiency. His work bridges computational neuroscience with practical applications in medical diagnostics, embedded systems, and real-time signal processing. His team has made significant contributions to understanding consciousness in locked-in syndrome patients through EEG analysis and developing innovative approaches to agricultural quality control using hyperspectral imaging and neural networks. The research demonstrates a consistent trajectory from foundational neural network architectures toward increasingly sophisticated neuromorphic computing applications. Analysis of Professor Bogdan's recent publication record reveals a strong focus on advancing spiking neural network architectures, particularly liquid state machines and synaptic dynamics models. His work increasingly bridges theoretical neuroscience with practical applications in medical diagnostics (particularly consciousness assessment in locked-in syndrome patients) and agricultural technology (using hyperspectral imaging for seed purity analysis). A notable emerging theme is the exploration of cognitive concepts like boredom in artificial intelligence systems, suggesting expanding interest in higher-order cognitive modeling within neuromorphic computing frameworks. Professor Bogdan leads the Department of Neuromorphic Information Processing at the University of Leipzig, supervising numerous PhD students and postdoctoral researchers. His team includes researchers specializing in various aspects of neural networks, signal processing, and applications in medical and agricultural domains. The department maintains active collaborations with medical institutions for clinical applications of their research, particularly in the area of brain-computer interfaces and consciousness assessment.

• Cancer Genomics
• Molecular Oncology
• Precision Medicine
• +۵ مورد دیگر

Claudio Isella serves as an Associate Professor in the Department of Oncology at the University of Torino's School of Medicine. His research focuses on molecular oncology, cancer genomics, and precision medicine approaches to gastrointestinal cancers. Department of Oncology, University of Torino Member of Department Council Member of Commissione per la Ricerca PhD program involvement in Complex Systems for Quantitative Biomedicine Dr. Isella's research interests center on cancer genomics, molecular oncology, and precision medicine with particular emphasis on colorectal cancer, patient-derived xenografts (PDX), and transcriptomics. His work integrates computational biology approaches with experimental models to understand cancer biology and identify therapeutic vulnerabilities. He has made significant contributions to understanding tumor evolution, drug resistance mechanisms, and biomarker discovery for precision oncology applications. Analysis of Dr. Isella's recent publications reveals a strong focus on patient-derived xenograft models for cancer research, molecular subtyping of gastrointestinal malignancies, and identification of therapeutic targets through genomic and transcriptomic approaches. His work spans colorectal cancer, gastric cancer, and other solid tumors with emphasis on translating molecular findings into clinically relevant insights for precision medicine applications. Dr. Isella teaches courses including Histology (INT0652), Multi-omics and Data Science for Precision Medicine (ONC0260), and Artificial Intelligence for Biomedicine and Healthcare. His teaching integrates molecular biology with computational approaches reflecting his research expertise.

• Cancer Genomics
• Immunotherapy
• Neuro-Oncology
• +۳ مورد دیگر

Josephine Deleuran Hendriksen is a Guest Researcher in the Weischenfeldt Group at the Biotech Research and Innovation Centre (BRIC), University of Copenhagen, specializing in cancer genomics and immunotherapy. Her work bridges molecular oncology and clinical translation with a focus on aggressive malignancies. Her research centers on tumor microenvironment dynamics and molecular evolution of cancers , particularly investigating immunotherapy-induced mesenchymal shifts in glioblastoma and genomic risk markers in early-onset prostate cancer. This reflects expertise in high-throughput genomic analysis and tumor-immune interactions. Publications demonstrate a trajectory toward understanding therapy resistance mechanisms, with recent work highlighting immune reprogramming in glioblastoma (2024) building on foundational prostate cancer evolution studies (2018). Both papers appeared in top-tier oncology journals with significant citation impact. She operates within the Weischenfeldt Group at BRIC, a translational cancer research hub leveraging genomic technologies to address clinical challenges in neuro-oncology and urological cancers.

• Molecular Imaging
• Cancer Diagnostics
• Peptide Therapeutics
• +۵ مورد دیگر

Julie Maja Leth is a researcher at the Biotech Research & Innovation Centre (BRIC) within the University of Copenhagen, working in the Ploug Group. Her research focuses on the urokinase-type plasminogen activator receptor (uPAR) and its applications in cancer diagnostics and therapeutics. She maintains an active research profile with publications spanning molecular imaging, peptide engineering, and biochemical analysis of protein interactions. Her research interests center on developing molecular imaging techniques for cancer detection, particularly through uPAR-targeted approaches. This includes creating peptide-based imaging agents for fluorescence-guided surgery, optimizing radiolabeling techniques for PET imaging, and investigating the structural biology of uPAR interactions. Her work bridges biochemistry, oncology, and medical imaging to develop novel diagnostic and therapeutic strategies. Analysis of her publication record shows consistent contributions to molecular imaging techniques, with particular emphasis on uPAR-targeted applications across multiple cancer types. Her research demonstrates progression from fundamental biochemical studies of protein interactions toward translational applications in surgical oncology and diagnostic imaging. Dr. Leth actively collaborates with the Ploug and Kjaer research groups at BRIC, contributing to both basic science investigations of protein receptor biology and applied research in cancer diagnostics. Her work has been referenced in multiple patents, indicating translational potential of her research. Her laboratory work centers on the Ploug Group at BRIC, where she investigates uPAR receptor biology using biochemical, biophysical, and imaging approaches. The research environment supports both fundamental studies of protein interactions and applied development of imaging agents for clinical translation.